🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

30 results for “H.” Clear

  1. CYTARABINE, CYTARABINE, Liposomal Annamycin, 0.9% Sodium Chloride Injection, USP/Ph. Eur./BP/JP

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 small molecule active

    1 trial

  3. H. pylori vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  4. Kreon 35 000 Ph. Eur. Lipase Einheiten, magensaftresistente Hartkapseln

    Pharma Mar S.A.

    Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).

    phase 3 small molecule active

    1 trial

  5. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  6. TAK-438

    Takeda Pharmaceuticals International AG

    H. Pylori Infection

    phase 3 small molecule completed

    1 trial

  7. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Chronic migraine

    phase 3 small molecule active

    1 trial

  8. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  9. VYEPTI 100 mg concentrate for solution for infusion, Nacl 0.9%

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  10. commercially available saline solution for infusion, Amlenetug 53 mg/ml solution for infusion

    H. Lundbeck A/S

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  11. A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease

    H. Lundbeck A/S

    Cushing's Disease

    phase 2 other active

    1 trial

  12. HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE

    Novartis Ophthalmics Europe

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  13. Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab)

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  14. Placebo to match IMP Lu AG09222

    H. Lundbeck A/S

    Migraine

    phase 2 small molecule active

    1 trial

  15. A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  16. A study to test the safety and tolerability of Lu AH69593 in adults that are healthy or have narcolepsy.

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial

  17. A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults.

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial

  18. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects und

    Pharma Mar S.A.

    Epilepsy

    phase 1 other active

    1 trial

  19. Creon 25.000, harde maagsapresistente capsules 25.000 eenheden, Creon 50000 Ph.Eur. lipase units, Creon 25000 Ph.Eur. lipase units, Creon 10000 Ph.Eur. lipase units, Creon 75000 Ph.Eur. lipase units, Creon® 10000 Capsules

    Pharma Mar S.A.

    patients with cystic fibrosis suffering from pancreatic exocrine insufficiency

    phase 1 small molecule active

    1 trial

  20. Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial

  21. Lu AF28996 in Patients With Parkinson's Disease

    H. Lundbeck A/S

    Parkinson's Disease

    phase 1 other active

    1 trial

  22. RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

    Rocket Pharmaceuticals B.V.

    Dilated Cardiomyopathy (DCM)

    phase 1 gene therapy active

    1 trial

  23. COLECALCIFEROL , The Placebo product consists only of pure Ph. Eur. refined olive and it differs from Test product for the absence of active substance only: therefore, there are no reasons to suspect that the placebo product will undergo changes in its physical characteristics or degradation., Placebo

    Fondazione Telethon ETS

    obese elderly people with vitamin D deficiency

    approved small molecule active

    1 trial

  24. FLUCORTAC 50 microgrammes, comprimé sécable, Cellulose microcristalline 50 microgrammes

    H.A.C. Pharma

    Neurogenic Orthostatic Hypotension

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources